Long-term use of metformin and colorectal cancer risk in type II diabetics: A population-based case-control study

Cancer Medicine

Volumn 3, Issue 5, 2014, Pages 1458-1466

  Cardel, Majken ^a   Jensen, Sara M ^b   Pottegård, Anton ^b   Jørgensen, Trine L ^c   Hallas, Jesper ^b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer prevention; Colorectal cancer; Metformin; Population based case control study; Type II diabetes mellitus

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG INDICATION; FEMALE; HUMAN; LONG TERM CARE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; COMPLICATION; DIABETES MELLITUS, TYPE 2; HEALTH SURVEY; MIDDLE AGED; ODDS RATIO; REGISTER; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; ODDS RATIO; POPULATION SURVEILLANCE; REGISTRIES;

EID: 84991494403     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.306     Document Type: Article

References (43)

1. Ben Sahra, I., Y. Le Marchand-Brustel, J. F. Tanti, and F. Bost. 2010. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol. Cancer Ther. 9:1092-1099.
2. Region S. Basislisten, 2011. web, acces-querty. Available at: http://www.basislisten.dk/Syddanmark/Diabetes.htm (accessed 9 May 2012).
3. Zhang, Z. J., Z. J. Zheng, H. Kan, Y. Song, W. Cui, G. Zhao, et al. 2011. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 34:2323-2328.
4. Decensi, A., M. Puntoni, P. Goodwin, M. Cazzaniga, A. Gennari, B. Bonanni, et al. 2010. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Pre. Res. (Phila) 3:1451-1461.
5. Noto, H., A. Goto, T. Tsujimoto, and M. Noda. 2012. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 7:e33411.
6. Tomimoto, A., H. Endo, M. Sugiyama, T. Fujisawa, K. Hosono, H. Takahashi, et al. 2008. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 99:2136-2141.
7. Hosono, K., H. Endo, H. Takahashi, M. Sugiyama, E. Sakai, T. Uchiyama, et al. 2010. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Pre. Res. (Phila) 3:1077-1083.
8. Jalving, M., J. A. Gietema, J. D. Lefrandt, S. Jong de, A. K. Reyners, R. O. Gans, et al. 2010. Metformin: taking away the candy for cancer? Eur. J. Cancer 46:2369-2380.
9. Wang, W., and K. L. Guan. 2009. AMP-activated protein kinase and cancer. Acta Physiol. (Oxf) 196:55-63.
10. Hadad, S. M., S. Fleming, and A. M. Thompson. 2008. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit. Rev. Oncol. Hematol. 67:1-7.
11. Luo, Z., M. Zang, and W. Guo. 2010. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 6:457-470.
12. Luo, Z., A. K. Saha, X. Xiang, and N. B. Ruderman. 2005. AMPK, the metabolic syndrome and cancer. Trends Pharmacol. Sci. 26:69-76.
13. Jones, R. G., D. R. Plas, S. Kubek, M. Buzzai, J. Mu, Y. Xu, et al. 2005. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18:283-293.
14. Meijer, A. J., and P. Codogno. 2011. Autophagy: regulation by energy sensing. Curr. Biol. 21:R227-R229.
15. Franciosi, M., G. Lucisano, E. Lapice, G. F. Strippoli, F. Pellegrini, and A. Nicolucci. 2013. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE 8:e71583.
16. Engholm, G. F. J., N. Christensen, T. B. Johannesen, Å. Klint, J. E. Køtlum, M. C. Milter, et al. 2009. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, ed. Version 5.1, Association of the Nordic Cancer Registries, Copenhagen.
17. Gjerstorff, M. L. 2011. The Danish Cancer Registry. Scand. J. Public Health 39:42-45.
18. Storm, H. H., E. V. Michelsen, I. H. Clemmensen, and J. Pihl. 1997. The Danish Cancer Registry-history, content, quality and use. Dan. Med. Bull. 44:535-539.
19. Lynge, E., J. L. Sandegaard, and M. Rebolj. 2011. The Danish National Patient Register. Scand. J. Public Health 39:30-33.
20. Kildemoes, H. W., H. T. Sorensen, and J. Hallas. 2011. The Danish National Prescription Registry. Scand. J. Public Health 39:38-41.
21. Pedersen, C. B. 2011. The Danish Civil Registration System. Scand. J. Public Health 39:22-25.
22. Rothman, K. J. 2002. Epidemiology, an introduction.Oxford University Press, New York.
23. organization Wh. DDD for metformin, vol. 2012, 2012.
24. Pottegård, A., S. Friis, and J. Hallas. 2013. Cancer risk in long-term users of vitamin K antagonists: a population-based case-control study. Int. J. Cancer 132:2606-2612.
25. Hallas, J., D. Gaist, and L. Bjerrum. 1997. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology 8:666-670.
26. Lægemiddelstyrelsen. 2012. MEDSTAT MEDSTAT, vol. 2012. Lægemiddelstyrelsen, Statens Serum Institut, Copenhagen.
27. Yang, Y. X., S. Hennessy, and J. D. Lewis. 2004. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044-1050.
28. Morden, N. E., S. K. Liu, J. Smith, T. A. Mackenzie, J. Skinner, and M. Korc. 2011. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 34:1965-1971.
29. Lee, M. S., C. C. Hsu, M. L. Wahlqvist, H. N. Tsai, Y. H. Chang, and Y. C. Huang. 2011. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer 11:20.
30. Currie, C. J., C. D. Poole, and E. A. Gale. 2009. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777.
31. Libby, G., L. A. Donnelly, P. T. Donnan, D. R. Alessi, A. D. Morris, and J. M. Evans. 2009. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625.
32. Devita, V. T., Jr., T. S. Lawrence, and S. A. Rosenberg. 2008. Pp. 1218-1227 in Devita, Hellman and Rosenberg's cancer, principles & practice of oncology, vol. 236, 8 ed. Wolters Kluwer/Lippincott Williams & Wilkins.
33. Canavan, C., K. R. Abrams, and J. Mayberry. 2006. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment. Pharmacol. Ther. 23:1097-1104.
34. Ruiter, R., L. E. Visser, M. P. van Herk-Sukel, J. W. Coebergh, H. R. Haak, P. H. Geelhoed-Duijvestijn, et al. 2012. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 35:119-124.
35. Lyons, M. R., L. R. Peterson, J. B. McGill, P. Herrero, A. R. Coggan, I. M. Saeed, et al. 2013. Impact of sex on the heart's metabolic and functional responses to diabetic therapies. Am. J. Physiol. Heart Circ. Physiol. 305:H1584-H1591.
36. Tzoulaki, I., M. Molokhia, V. Curcin, M. P. Little, C. J. Millett, A. Ng, et al. 2009. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731.
37. Pandey, A., V. Forte, M. Abdallah, A. Alickaj, S. Mahmud, S. Asad, et al. 2011. Diabetes mellitus and the risk of cancer. Minerva Endocrinol. 36:187-209.
38. Larsson, S. C., N. Orsini, and A. Wolk. 2005. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J. Natl. Cancer Inst. 97:1679-1687.
39. Cheng, M. H., H. F. Chiu, S. C. Ho, S. S. Tsai, T. N. Wu, and C. Y. Yang. 2011. Statin use and the risk of colorectal cancer: a population-based case-control study. World J. Gastroenterol. 17:5197-5202.
40. Grahn, S. W., and M. G. Varma. 2008. Factors that increase risk of colon polyps. Clin. Colon Rectal Surg. 21:247-255.
41. Fedirko, V., I. Tramacere, V. Bagnardi, M. Rota, L. Scotti, F. Islami, et al. 2011. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann. Oncol. 22:1958-1972.
42. Ning, Y., L. Wang, and E. L. Giovannucci. 2010. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes. Rev. 11:19-30.
43. Rang, H. P., M. M. Dale, J. M. Ritter and R. J. Flower. 2011. P. 639 in Pharmacology. 7 ed. Churchill Livingstone Elsevier, Edinburgh.